CHROMIC CHLORIDE (chromic chloride) by Bristol Myers Squibb is clinical pharmacology trivalent chromium is part of glucose tolerance factor, an essential activator of insulin-mediated reactions. Approved for depletion of endogenous stores, subsequent deficiency symptoms. First approved in 1987.
Drug data last refreshed 12h ago · AI intelligence enriched 5d ago
Chromic Chloride is an injectable trace mineral supplement containing trivalent chromium, an essential cofactor for glucose tolerance factor and insulin-mediated glucose metabolism. It is indicated for prevention and treatment of chromium deficiency in patients receiving total parenteral nutrition (TPN). Chromium administration restores normal glucose tolerance curves and prevents neurological complications associated with deficiency.
As LOE approaches, brand team focus shifts from growth defense to lifecycle extension strategies; reduced headcount typical for niche nutritional products.
CLINICAL PHARMACOLOGY Trivalent chromium is part of glucose tolerance factor, an essential activator of insulin-mediated reactions. Chromium helps to maintain normal glucose metabolism and peripheral nerve function. Providing chromium during TPN helps prevent deficiency symptoms including impaired…
Worked on CHROMIC CHLORIDE at Bristol Myers Squibb? Share your interview experience or compensation data (+7 days Pro)
The information on this page is for informational purposes only and should not be used as a substitute for professional medical advice. Drug information is sourced from FDA, DailyMed, and other government databases. Adverse event data from FAERS does not establish causation. Always consult a healthcare professional for medical decisions.
Working on Chromic Chloride offers limited external career visibility but deep expertise in niche nutritional pharmacology and hospital-based TPN management. Roles emphasize compliance, supply stability, and clinical relationships with ICU/nutritional support teams rather than growth-oriented commercial strategy.